Duromine vs Ozempic in the Philippines

Duromine is phentermine in a modified-release capsule, registered with FDA Philippines under DR-XY26998 in 15mg and 30mg strengths, and classified prescription-only. Ozempic is semaglutide, a GLP-1 receptor agonist whose registered indication is type 2 diabetes, sold through Philippine pharmacy counters on prescription.

The useful framing is not which drug is stronger. It is that these two answer different questions. Duromine is a defined course with a label limit of three months. Ozempic is a medicine for continuing use. A comparison that ignores the duration difference is comparing a sprint to a standing arrangement.

Three things are worth knowing before the table. First, the published efficacy figures for semaglutide at its weight-management dose are larger than those summarised for phentermine, although the trials are not comparable. Second, the Duromine half of any price comparison cannot be verified, because no Philippine pharmacy publishes a Duromine price. Third, the GLP-1 side has a supply problem: Manila Bulletin reported on 13 June 2026 that Philippine pharmacies were rationing Ozempic pens.

Every Ozempic peso figure below was read from the pharmacy’s own product page on 23 September 2026. Philippine pharmacy pricing moves fast and varies by branch.

Sources for the cells above are named in the sections that follow. Where a cell says not published, that is what was found, not an estimate withheld.

Duromine is phentermine. The Duromine product information describes it as a sympathomimetic amine acting on dopaminergic and noradrenergic systems, with appetite suppression “generally considered to be exerted through the hypothalamus”. In plain terms it turns down hunger by stimulating the nervous system. That is also why the side effect list reads the way it does: insomnia, nervousness, tremor, dry mouth, raised blood pressure and changes in heartbeat are the expected consequences of the mechanism, not incidental to it.

Ozempic is semaglutide, an analogue of GLP-1, a hormone the gut releases after a meal. It works with the incretin system rather than the adrenergic one: it slows gastric emptying, amplifies glucose-dependent insulin release and acts on satiety signalling. Its side effect profile is gastrointestinal for the same reason the stimulant’s is cardiovascular.

This is why the two cannot be ranked on a single axis. Uncontrolled hypertension, a psychiatric history, hyperthyroidism, glaucoma or a history of substance misuse are explicit contraindications in the Duromine product information. A personal or family history of medullary thyroid carcinoma is a contraindication for semaglutide instead. Neither list is a suggestion, and neither is something a comparison page can screen a patient against.

The Cleveland Clinic Journal of Medicine, reviewing obesity pharmacotherapy, summarised a pooled analysis of phentermine trials spanning 1975 to 1999 in which patients lost roughly 3.6kg more than those on placebo. The best single result it cites is a 36-week study with mean losses of 12.2kg on continuous phentermine against 4.8kg on placebo, a single older study rather than a modern registration programme.

Semaglutide has that modern programme. STEP 1, a phase 3 trial published in the New England Journal of Medicine, randomised 1,961 adults with overweight or obesity without diabetes and ran for 68 weeks. Mean body weight change was 14.9% on semaglutide 2.4 mg against 2.4% on placebo. On side effects, STEP 2, a phase 3 trial in adults with type 2 diabetes, reported gastrointestinal adverse events in 57.5% of its semaglutide 1.0 mg arm against 34.3% on placebo.

There is one more asymmetry worth naming. The phentermine studies summarised above are mostly short and mostly old. That does not make phentermine ineffective. It does mean the comparison is between a drug with a large recent dataset and a drug with a small old one, and the two should be weighed differently rather than read as equivalent evidence.

On the GLP-1 side the numbers are public and easy to check. On 23 September 2026 Watsons Philippines listed the Ozempic 0.5mg/0.37ml pen at ₱8,187.50 and the 1mg/0.74ml pen at ₱9,280, both flagged prescription required. Those are pen prices only; the consultation that produces the prescription is separate.

Manila Bulletin reported on 13 June 2026 that Ozempic had earlier sold for around ₱6,200 to ₱6,300 before prices rose, and that one Las Piñas pharmacy quoted ₱11,368 for the 1 mg pen. The same report is the clearest published account of Philippine rationing, with pharmacists describing branch limits of two pens per dosage per month and screening customers to keep supply flowing to diabetic patients.

On the Duromine side there is nothing to quote, and that is the finding. Watsons Philippines, Southstar Drug and MedsGo all publish peso prices for Ozempic. None of the three listed Duromine when checked in August 2026. The Philippine figures that circulate for it come from classified listings and forum threads, which are resale prices rather than pharmacy prices, and this site does not print them. The Duromine Philippines filing covers why no pharmacy figure exists.

Philippine pharmacy pricing changes without notice and varies by branch. Confirm at the counter before relying on any figure here.

The single most practical difference between these two drugs is not efficacy or price. It is that one of them has an end point written into its label and the other does not.

The Duromine product information is unambiguous: patients require medical review after a defined course of treatment, which “should not exceed three months”. It is indicated as a short-term adjunct alongside exercise, diet and behaviour modification, for people with a BMI of 30 or above, or 25 to 29.9 with additional risk. That is a defined intervention with a defined end, and the behaviour change is meant to be the durable part.

Ozempic carries no such limit because it is a chronic medicine for a chronic disease. What happens after stopping is documented for semaglutide: in STEP 4, adults who reached 2.4 mg over a 20-week run-in and were then switched to placebo regained 6.9% of body weight by week 68, while those who continued changed by a further 7.9%. Neither drug is a cure and neither claims to be, but they differ by design: the stimulant is designed to end, and the incretin is designed to continue.

On tolerance and dependence, the literature is more measured than the internet is. The Duromine product information notes only that “inappropriate use has been reported with similar drugs and the possibility of this occurrence should be considered with Duromine”. The Cleveland Clinic Journal of Medicine, while recording that phentermine is a schedule IV controlled substance in the United States, states that concerns about addiction and dependence with phentermine are largely unfounded, and that abrupt cessation has not been shown to cause amphetamine-like withdrawal. The three-month limit is better understood as a cardiovascular and review requirement than as a withdrawal one. It is still a limit, and it is still on the label.

One side of this comparison has a documented supply problem. Manila Bulletin’s report of 13 June 2026 described Philippine pharmacies imposing monthly allocation limits on Ozempic, pharmacists deciding which customers to serve, patients travelling between branches, and at least one patient going a month without medication because nothing was available locally.

When a registered channel rations, an unregistered one fills the gap. Under RA 9711 a drug must be registered with FDA Philippines before it is imported, sold or distributed; the detail is in the regulation hub. This site maintains a counterfeit Ozempic filing for that reason.

Duromine has a different problem: it is not visibly listed by the large Philippine online pharmacies at all. In both cases the dependable route is the same: a consultation with a licensed Philippine physician, a written prescription, and a registered pharmacy that asks to see it.